Abstract
In 2020, the IlluminoxⓇ platform was approved as a new cancer therapy. The IlluminoxⓇ platform is a generic term for a technology that uses light to kill cells by irradiating an agent that binds to cancer cells. Currently, AkaluxⓇ as the drug and the BioBladeⓇ laser system as the light irradiation system have been approved. AkaluxⓇ is an antibody photosensitizer conjugate, and IR700 （photosensitizer） is conjugated to anti-EGFR antibody. This drug is administered intravenously, and laser irradiation is performed one day later.
